Polynovo Ltd (ASX: PNV) Share Price and News
Price
$1.18
Movement
0.085 (-6.72%)
as at 13 Jun - Closed (20 mins delayed)
52 Week Range
$0.93 - $2.78
1 Year Return
-50.0%
Polynovo Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$815.19 million
P/E Ratio
155.36
Dividend Yield
0.00%
Shares Outstanding
690.84 million
Earnings per share
0.008
Dividend per share
N/A
Year To Date Return
-36.03%
Earnings Yield
0.64%
Franking
-
Share Price
$1.18
Day Change
0.085 (-6.72%)
52 Week Range
$0.93 - $2.78
Yesterday's Close
$1.265
Today's Open
$1.265
Days Range
$1.155 - $1.265
Volume
3,105,313
Avg. Volume (1 month)
2,169,971
Turnover
$3,705,063
as at 13 Jun - Closed
Polynovo Ltd (ASX: PNV)
Latest News
Share Gainers
The Polynovo (ASX:PNV) share price is up 5% on Thursday
Share Gainers
Polynovo (ASX:PNV) share price flat as revenue grows 32% in FY21
Healthcare Shares
How did the Polynovo (ASX:PNV) share price respond last earnings season?
Share Market News
These are the 10 most shorted ASX shares
Share Market News
The Polynovo (ASX:PNV) share price is up 7% this month. Here's why
Share Market News
These are the 10 most shorted ASX shares
Healthcare Shares
The best and worst performing ASX 200 healthcare shares of 2021
Share Market News
These are the 10 most shorted ASX shares
Share Market News
These are the 10 most shorted ASX shares
Share Fallers
These were the worst performing ASX 200 shares in July
Share Market News
ASX 200 Weekly Wrap: Just like that… ASX back to record highs
Share Gainers
These were the best performing ASX 200 shares last week
Frequently Asked Questions
-
The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was listed on the ASX on 26 November 1998 and is headquartered in Melbourne.
-
No, the company does not historically pay dividends.
PNV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| 21st May 2025 2025-05-21T16:21:40 | Becoming a substantial holder | YesNo | 4:21pm | 17 | 695k |
| 16th May 2025 2025-05-16T15:06:39 | Webcast Recording - Investor Update | YesNo | 3:06pm | 1 | 227k |
| 16th May 2025 2025-05-16T08:23:27 | Investor Presentation & Webcast Link | YesNo | 8:23am | 7 | 799k |
| 13th May 2025 2025-05-13T13:26:35 | BTM delivers positive First in Man results in Cell Therapies | YesNo | 1:26pm | 4 | 391k |
| 12th May 2025 2025-05-12T16:18:47 | Trading Halt | YesNo | 4:18pm | 2 | 263k |
| 12th May 2025 2025-05-12T14:44:07 | TGA Clearance for NovoSorb MTX (4 mm and 6 mm) | YesNo | 2:44pm | 2 | 226k |
| 7th May 2025 2025-05-07T13:28:14 | PolyNovo presents at Macquarie Australia Conference | YesNo | 1:28pm | 9 | 1.7M |
| 1st May 2025 2025-05-01T16:46:02 | Investor Update Webinar - 16 May 2025 | YesNo | 4:46pm | 2 | 279k |
| 22nd Apr 2025 2025-04-22T15:16:01 | Change in substantial holding | YesNo | 3:16pm | 25 | 2.3M |
| 22nd Apr 2025 2025-04-22T08:21:59 | Change in substantial holding | YesNo | 8:21am | 25 | 1.7M |
About Polynovo Ltd
PolyNovo Ltd (ASX: PNV) develops and commercialises innovative medical devices using its patented NovoSorb technology.
NovoSorb is a family of biocompatible polymers that are used in the treatment of burns and surgical wounds. They biodegrade into by-products that can be absorbed and excreted by the body. For example, its NovoSorb BTM (Biodegradable Temporising Matrix) can be used to temporarily close a wound and aid the body in generating new tissue.
PolyNovo’s products are sold across Australia and New Zealand, the United States, the United Kingdom, and Europe.
PNV Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Jun 2025 | $1.18 | $-0.09 | -7.11% | 3,105,313 | $1.27 | $1.27 | $1.16 |
| 12 Jun 2025 | $1.27 | $-0.04 | -3.07% | 2,335,785 | $1.30 | $1.30 | $1.26 |
| 11 Jun 2025 | $1.31 | $-0.04 | -2.97% | 2,589,203 | $1.36 | $1.38 | $1.30 |
| 10 Jun 2025 | $1.35 | $0.03 | 2.29% | 1,829,089 | $1.31 | $1.35 | $1.30 |
| 06 Jun 2025 | $1.31 | $-0.03 | -2.24% | 1,082,756 | $1.36 | $1.36 | $1.30 |
| 05 Jun 2025 | $1.34 | $0.03 | 2.28% | 2,733,737 | $1.32 | $1.37 | $1.32 |
| 04 Jun 2025 | $1.32 | $0.05 | 3.95% | 1,389,990 | $1.28 | $1.34 | $1.28 |
| 03 Jun 2025 | $1.27 | $0.00 | 0.00% | 1,023,591 | $1.27 | $1.28 | $1.25 |
| 02 Jun 2025 | $1.26 | $-0.05 | -3.82% | 1,312,053 | $1.32 | $1.33 | $1.26 |
| 30 May 2025 | $1.31 | $0.01 | 0.77% | 1,742,811 | $1.30 | $1.33 | $1.28 |
| 29 May 2025 | $1.31 | $0.01 | 0.78% | 740,284 | $1.29 | $1.32 | $1.29 |
| 28 May 2025 | $1.29 | $0.01 | 0.78% | 1,633,894 | $1.30 | $1.33 | $1.29 |
| 27 May 2025 | $1.29 | $-0.02 | -1.54% | 2,411,210 | $1.31 | $1.32 | $1.26 |
| 26 May 2025 | $1.30 | $0.00 | 0.00% | 1,242,079 | $1.31 | $1.32 | $1.28 |
| 23 May 2025 | $1.31 | $-0.01 | -0.76% | 1,507,695 | $1.31 | $1.32 | $1.28 |
| 22 May 2025 | $1.31 | $-0.05 | -3.66% | 2,629,588 | $1.35 | $1.36 | $1.29 |
| 21 May 2025 | $1.37 | $-0.01 | -0.73% | 1,816,547 | $1.38 | $1.41 | $1.36 |
| 20 May 2025 | $1.38 | $-0.06 | -4.18% | 3,415,741 | $1.42 | $1.43 | $1.36 |
| 19 May 2025 | $1.44 | $-0.05 | -3.36% | 2,163,444 | $1.51 | $1.53 | $1.41 |
| 16 May 2025 | $1.49 | $0.00 | 0.00% | 1,911,607 | $1.50 | $1.53 | $1.46 |
| 15 May 2025 | $1.49 | $-0.02 | -1.32% | 2,369,534 | $1.50 | $1.54 | $1.46 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 10 Jan 2025 | David Williams | Sell | 750 | $1,522 |
Off-market trade.
|
| 30 Sep 2024 | Andrew Lumsden | Sell | 50,000 | $130,915 |
On-market trade.
|
| 26 Sep 2024 | Leon Hoare | Sell | 100,000 | $260,839 |
On-market trade. As per announcement on 02-01-2024
|
| 13 Sep 2024 | Bruce Rathie | Sell | 750,000 | $1,886,900 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr David Williams | Non-Executive DirectorNon-Executive Chairman | Feb 2014 |
Mr Williams is a director and investment banker with a track record in business development, mergers and acquisitions, and capital raising. He has experience advising companies in the food, medical device, and pharmaceutical sectors. Mr Williams is currently Managing Director of corporate advisory firm Kidder Williams.
|
| Dr Robyn Elliott | Non-Executive Director | Oct 2019 |
Dr Elliott has a track record in product development, clinical trials, regulatory affairs, audits, quality management, project management and operational strategy. Her worldwide experience in new facility delivery, production scale up, strategy, regulatory affairs and audit will be invaluable to PolyNovo as the company scales its operations globally. Dr Elliott was Global Head, Strategic Portfolio Management at CSL Behring, a role that is responsible for governance oversight and business value delivery. Dr Elliott is a member of the Risk Committee.
|
| Mr Andrew Stuart Lumsden | Non-Executive Director | Jun 2021 |
Mr Lumsden has more than 20 years of experience locally and internationally. Mr Lumsden is currently Chief Executive Officer of Wellcom Worldwide Australasia having previously held the roles of Group Chief Financial Officer and Group Chief Operating Officer. Prior to joining Wellcom, Mr Lumsden was a Senior Manager within the Audit and Assurance practice of PricewaterhouseCoopers. Mr Lumsden is the Chair of the Risk Committee.
|
| Mr Leon Hoare | Non-Executive Director | Jan 2016 |
Mr Hoare has expertise across multiple Life Sciences sectors. He is currently the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company. Previously he was Managing Director of Smith & Nephew (S&N) ANZ. He served as President of S&N's Asia-Pacific Advanced Wound Management (AWM) businesses for 5 years and was a member of the Global Executive Management for the AWM Division.
|
| Ms Christine Emmanuel-Donnelly | Non-Executive Director | May 2020 |
Ms Emmanuel-Donnelly is an IP and business development professional with more than 30 years of local and international experience. She has been on the Board of the Institute of Patent and Trademark Attorneys of Australia for over a decade. Ms Emmanuel-Donnelly was Executive Manager of Business Development and Commercial at the CSIRO, was in-house IP Counsel for Unilever in the U.K., and practiced as a patent and trademark attorney for Wilson Gunn.
|
| Mr Jan-Marcel Gielen | Company Secretary | Dec 2018 |
-
|
| Mr Swami Raote | Chief Executive Officer | Jul 2022 |
-
|
| Swami Raote | Chief Executive Officer |
-
|
|
| Jan Gielen | Chief Financial Officer |
-
|
|
| Philip Scorgie | Chief Information Officer |
-
|
|
| Joseph Amaral | Chief Medical Officer (part-time) |
-
|
|
| Ingrid Anderson | Chief People Officer |
-
|
|
| David McQuillan | Chief Technical and Scientific Officer |
-
|
|
| Jan-Marcel Gielen | Company Secretary |
-
|
|
| David Morris | President Asia Pacific |
-
|
|
| Edward Graubart | President North America |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hsbc Custody Nominees (Australia) Limited | 96,149,727 | 13.93% |
| J P Morgan Nominees Australia Pty Limited | 80,078,534 | 11.60% |
| Citicorp Nominees Pty Limited | 37,720,578 | 5.46% |
| Moggs Creek Pty Ltd (Moggs Creek Super A/C) | 19,010,112 | 2.75% |
| Lateral Innovations Pty Ltd (Trust A/C | 10,924,103 | 1.58% |
| Mr Anthony Shane Kittel Mrs Michele Therese Kittel (Kittel Family Super A/C) | 8,050,000 | 1.17% |
| Bnp Paribas Noms Pty Ltd | 7,622,413 | 1.10% |
| National Nominees Limited | 6,653,041 | 0.96% |
| Netwealth Investments Limited (Wrap Services A/C) | 5,394,880 | 0.74% |
| BNP Paribas Nominees Pty Ltd (IB AU Noms Retailclient) | 4,533,452 | 0.66% |
| BNP Paribas Nominees Pty Ltd (Agency Lending A/C) | 4,414,903 | 0.64% |
| Commonwealth Scientific And Industrial Research Organisation | 4,081,250 | 0.59% |
| Mrs Li-Hsien Tsai | 3,955,424 | 0.57% |
| Mr David Kenley | 3,755,000 | 0.54% |
| Mr Paul Gerard Brennan | 3,569,796 | 0.52% |
| Mr Matthew James Avery | 3,439,332 | 0.50% |
| Mr David Kenley i | 3,139,855 | 0.45% |
| Dr Marcus James Dermot Wagstaff Mrs Lara Kate Wagstaff | 3,072,166 | 0.45% |
| Mr Evan Philip Clucas Ms Leanne Jane Weston (Kuranga Nursery Super A/C) | 2,931,149 | 0.42% |
| Mr Chris Dawborn (Haskali Super Fund A/C) | 2,870,271 | 0.42% |